Efficiency of CYP2C9 Genetic Test Representation for Automated Pharmacogenetic Decision Support

被引:12
|
作者
Deshmukh, V. G. [1 ]
Hoffman, M. A. [2 ]
Arnoldi, C. [2 ]
Bray, B. E. [1 ]
Mitchell, J. A. [1 ]
机构
[1] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT 84112 USA
[2] Cerner Corp, Kansas City, MO USA
关键词
Pharmacogenetics; clinical decision support systems; SNP; allele; CYTOCHROME-P450; CYP2C9; DOSE REQUIREMENT; WARFARIN; METABOLISM; GENOMICS; ANTICOAGULATION; THERAPY;
D O I
10.3414/ME0570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives: We investigated the suitability of representing discrete genetic test results in the electronic health record (EHR) as individual single nucleotide polymorphisms (SNPs) and as alleles, using the CYP2C9 gene and its polymorphic states, as part of a pilot study. The purpose of our investigation was to determine the appropriate level of data abstraction when reporting genetic test results in the EHR that would allow meaningful interpretation and clinical decision support based on current knowledge, while retaining sufficient information in order to enable reinterpretation of the results in the context of future discoveries. Methods: Based on the SNP & allele models, we designed two separate lab panels within the laboratory information system, one containing SNPs and the other containing alleles, built separate rules in the clinical decision support system based on each model, and evaluated the performance of these rules in an EHR simulation environment using real-world scenarios. Results: Although decision-support rules based on allele model required significantly less computational time than rules based on SNP model, no difference was observed on the total time taken to chart medication orders between rules based on these two models. Conclusions: Both, SNP- and allele-based models, can be used effectively for representing genetic test results in the EHR without impacting clinical decision support systems. While storing and reporting genetic test results as alleles allow for the construction of simpler decision-support rules, and make it easier to present these results to clinicians, SNP-based model can retain a greater amount of information that could be useful for future reinterpretation.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 50 条
  • [21] Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells
    Usman, Muhammad
    Zhen-Han, Zhu
    Ze-Na, Chang
    Jun-Ping, Han
    Wen, Qian
    Chang-Qing, Yang
    Miyu, Nishikawa
    Toshiyuki, Sakaki
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 55
  • [22] An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62
    Chen, Hao
    Dai, Da-Peng
    Zhou, Shan
    Liu, Jian
    Wang, Shuang-Hu
    Wu, Hua-Lan
    Zhou, Quan
    Geng, Pei-Wu
    Chong, Jia
    Lu, You
    Cai, Jian-Ping
    Yang, Jie-Fu
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 327
  • [23] Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement
    Quinn, Alison L. H.
    Liko, Ina
    Lee, James C.
    PHARMACOGENOMICS, 2017, 18 (11) : 1051 - 1057
  • [24] CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies
    Villagra, David
    Duconge, Jorge
    Windemuth, Andreas
    Cadilla, Carmen L.
    Kocherla, Mohan
    Gorowski, Krystyna
    Bogaard, Kali
    Renta, Jessica Y.
    Cruz, Irelys A.
    Mirabal, Sara
    Seip, Richard L.
    Ruano, Gualberto
    CLINICA CHIMICA ACTA, 2010, 411 (17-18) : 1306 - 1311
  • [25] Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects
    Shaul, Chanan
    Blotnick, Simcha
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    MOLECULAR DIAGNOSIS & THERAPY, 2017, 21 (01) : 75 - 83
  • [26] CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
    Nizamuddin, Sheikh
    Dubey, Shivendra
    Singh, Sakshi
    Sharma, Saurav
    Machha, Pratheusa
    Thangaraj, Kumarasamy
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 135 - 147
  • [27] Warfarin Dosing in Patients with the CYP2C9*5 Variant
    Lindley, Kathryn
    Limdi, Nita
    Cavallari, Larisa H.
    Perera, Minoli
    Lenzini, Petra
    Johnson, Julie
    Wu, Alan
    Ridker, Paul
    Patel, Shitalben
    King, Cristi
    Shah, Shimoli
    Eby, Charles
    Beasley, T. Mark
    Gage, Brian F.
    CIRCULATION, 2010, 122 (21)
  • [28] The Relationship Between Warfarin Resistance and CYP2C9*2 and CYP2C9*3 Variations
    Kirac, Deniz
    Yaman, Aysun Erdem
    Doran, Tansu
    Altunok, Elif Cigdem
    MEDICAL JOURNAL OF BAKIRKOY, 2021, 17 (03) : 209 - 213
  • [29] Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
    Lee, H. W.
    Lim, M. -S.
    Lee, J.
    Jegal, M. -Y.
    Kim, D. -W.
    Lee, W. -K.
    Jang, I. -J.
    Shin, J. -G.
    Yoon, Y. -R.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (01) : 105 - 111
  • [30] The VKORC1 and CYP2C9 gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients - consideration of hypersensitivity and resistance
    Rakicevic, Ljiljana
    Kovac, Mirjana
    Radojkovic, Dragica
    Radojkovic, Milica
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2022, 150 (3-4) : 156 - 162